HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

3- cyano- N- (1,3- diphenyl- 1H- pyrazol- 5- yl)benzamide

affects mGluR5 receptors; structure in first source

Also Known As:

CDPPB

Networked: 16 relevant articles (2 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Wierońska, Joanna M: 2 articles (10/2021 - 09/2015)
2.	Perl, Stefanie: 2 articles (01/2020 - 09/2019)
3.	Richter, Angelika: 2 articles (01/2020 - 09/2019)
4.	Richter, Franziska: 2 articles (01/2020 - 09/2019)
5.	Schwendt, Marek: 2 articles (01/2019 - 03/2011)
6.	Ehmann, Megan: 1 article (01/2022)
7.	Markowski, Vincent P: 1 article (01/2022)
8.	Mattle, Anna: 1 article (01/2022)
9.	Miller-Rhodes, Patrick: 1 article (01/2022)
10.	Morris-Schaffer, Keith: 1 article (01/2022)

Related Diseases

1.	Memory Disorders (Memory Loss) 12/01/2019 - "Despite a four-week treatment did not prevent memory loss in aged transgenic mice, CDPPB is protective against Aβ stimulus. " 01/01/2015 - "Moreover, CDPPB chronic treatment was efficient to partially ameliorate motor incoordination and to rescue the memory deficit exhibited by BACHD mice. " 01/01/2015 - "Behavioral data suggest that the mGluRI hypofunction may underlie some of the cognitive abnormalities described in sdy mice as the administration of CDPPB (3-cyano-N-(1, 3-diphenyl-1H-pyrazol-5-yl benzamide), a positive allosteric modulator of mGluR5, rescued short-term object recognition and spatial learning and memory deficits in these mice. "
2.	Huntington Disease (Huntington's Disease) 01/01/2015 - "The mGluR5 positive allosteric modulator, CDPPB, ameliorates pathology and phenotypic signs of a mouse model of Huntington's disease."
3.	Schizophrenia (Dementia Praecox) 01/01/2022 - "These findings further support the use of neonatal MK-801 exposure as an animal model of schizophrenia and suggest that CDPPB can reverse the neurodevelopmental progression of some schizophrenia-like behaviors." 09/01/2015 - "GS39783 and CDPPB, positive allosteric modulators of GABAB and mGlu5 receptors, were previously shown to reverse behavioral phenotypes in animal models to mimic selected (predominantly positive) symptoms of schizophrenia. " 12/01/2021 - "This study analyzed whether the positive allosteric modulator of metabotropic glutamate receptor type 5 (mGlu5) 3-Cyano-N-(1,3-diphenyl-1H-pyrazol-5-yl) benzamide (CDPPB) would alleviate deficits in prepulse inhibition (PPI) and affect dopamine (DA) D2 signaling in the dorsal striatum and prefrontal cortex (PFC) in the neonatal quinpirole (NQ) model of schizophrenia (SZ). " 04/01/2010 - "MK-801 produces a deficit in sucrose preference that is reversed by clozapine, D-serine, and the metabotropic glutamate 5 receptor positive allosteric modulator CDPPB: relevance to negative symptoms associated with schizophrenia?"
4.	Cognitive Dysfunction 10/01/2021 - "CDPPB at a dose of 5 mg/kg ameliorated cognitive impairment in the passive avoidance test and partially reversed the changes in eNOS and nNOS expression induced by the lesion. " 10/01/2021 - "Neurochemical changes underlying cognitive impairment in olfactory bulbectomized rats and the impact of the mGlu5-positive allosteric modulator CDPPB." 03/01/2011 - "Here, we utilized a long-access meth self-administration (SA) protocol to assess recognition memory and metabotropic glutamate receptor (mGluR) expression, and the possible reversal of cognitive impairments with the mGluR5 allosteric modulator, 3-cyano-N-(1,3-diphenyl-1H-pyrazol-5-yl) benzamide (CDPPB). "
5.	Dyskinesias (Dyskinesia) 09/15/2019 - "Interestingly, CDPPB caused axial dyskinesia in addition to the dystonic symptoms in mutant hamsters. " 01/01/2020 - "CDPPB (10, 20 and 30 mg/kg intraperitoneal, i.p.) did not induce abnormal movements and the locomotor activity did not differ between DYT1 KI and wildtype mice. " 01/01/2020 - "Since DYT1 KI mice do not exhibit dystonic symptoms, we investigated if CDPPB provokes dystonia or dyskinesia. "

Related Drugs and Biologics

1.	benzamide
2.	Metabotropic Glutamate Receptors (Metabotropic Glutamate Receptor)
3.	Quinpirole
4.	Dopamine (Intropin)
5.	3- cyano- N- (1,3- diphenyl- 1H- pyrazol- 5- yl)benzamide
6.	Metabotropic Glutamate 5 Receptor
7.	Dizocilpine Maleate (Dizocilpine)
8.	Sucrose (Saccharose)
9.	Proteins (Proteins, Gene)
10.	GABA-B Receptor Agonists

Related Therapies and Procedures

1.	Self Administration (Administration, Self)